Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BNT3210
- Development stage
- Phase 2
- Lead developer
- BioNTech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BNT3210 is an investigational antibody-drug conjugate (ADC) developed by BioNTech that targets the tumor-associated carbohydrate antigen Sialyl-Tn (STn). Sialyl-Tn is a truncated O-glycan structure overexpressed in various epithelial cancers and solid tumors, while being virtually absent in healthy tissues. BNT3210 consists of a humanized IgG1 monoclonal antibody specific for Sialyl-Tn conjugated to a topoisomerase 1 inhibitor payload, specifically an exatecan derivative (DXd), via a cleavable linker. Upon binding to Sialyl-Tn on the surface of cancer cells, the ADC is internalized, releasing the cytotoxic payload to inhibit DNA topoisomerase 1, leading to DNA damage and cell death. BNT3210 is currently being evaluated in a Phase I/II clinical trial for the treatment of advanced solid tumors expressing Sialyl-Tn.
- Other names
- BNT 3210BNT3210BNT-3210
02
Targets
STn-MUC1 (Sialyl-Tn-MUC1)
Beyond the preview
Go deeper on BNT3210.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BNT3210.